A new test that tallies up useful immune cells in cancerous tissue could clarify a patient’s prognosis and possibly guide treatment, researchers say.
The technology counts helpful immune cells called tumor-infiltrating T lymphocytes. High counts of these cells in ovarian cancer patients have previously been associated with longer survival.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.